CompletedNot Applicable

Lymph Node Aspiration to Decipher the Immune Response of Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine.

France12 participantsStarted 2023-07-05

Plain-language summary

In order to investigate whether a germinal center response occurs following vaccine boost and to characterize it based on the type of vaccine received, we aim to analyze Spike and/or RBD-specific germinal center B cells within the draining lymph nodes. To achieve this, we will perform lymph node fine needle aspiration of the draining lymph node in 6 subjects in each study arm, 3 to 6 weeks after the booster vaccine injection.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or female aged 18 years and over included in COVIBOOST 2 Exclusion Criteria: * Hypersensitivity to lidocaine, to anaesthetics of the amide type or to any of the excipients * Patient with recurrent porphyrias

What they're measuring

The Spike and/or RBD-specific germinal center B cell response

Timeframe: Day 1

The Spike and/or RBD-specific germinal center B cell repertoire

Timeframe: Day 1

Trial details

NCT IDNCT05951920

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-07-22

View on ClinicalTrials.gov More COVID-19 trials